ERBB2 and breast cancer: In contrast, the induction of the c-Met/β1 complex in less aggressive “luminal” ER+PR+HER2– MCF7-iDimerize-c-Met-β1 breast cancer cells did not alter the low level of intravasation exhibited by these cells (P = 0.9; Supplemental Figure 4).